Hydrocortisone Acetate

Manufacturer
Paddock Laboratories, LLC
Effective date
2012-08-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
legacy-cache
Hydrated at
2026-08-02 01:45:33

Label at a glance#

ProductHydrocortisone Acetate
Active ingredientHYDROCORTISONE ACETATE
Label structure12 sections

Indications and uses

Hydrocortisone Acetate Suppositories are indicated for use in inflamed hemorrhoids, post irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.

Dosage and administration

One suppository in the rectum twice daily morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Each Hydrocortisone Acetate Suppository for rectal administration contains 30 mg hydrocortisone acetate in a hydrogenated cocoglyceride base.

Hydrocortisone acetate is a corticosteroid. The molecular weight of hydrocortisone acetate is 404.50. Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21- (acetyloxy)-11, 17- dihydroxy-, (11β)- with an empirical formula of C23H32O6 and the following structural formula:

Chemical Structure
Chemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.

Topical steroids are primarily effective because of their anti-inflammatory, antipruritic and vasoconstrictive action.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Hydrocortisone Acetate Suppositories are indicated for use in inflamed hemorrhoids, post irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hydrocortisone Acetate Suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.

PRECAUTIONS

PRECAUTIONS SECTION

Do not use unless adequate proctologic examination is made.

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Hydrocortisone Acetate Suppositories should be discontinued until the infection has been adequately controlled.

Carcinogenesis

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Pregnancy Category C and Nursing Mothers

PREGNANCY SECTION

NURSING MOTHERS SECTION

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.

It is not known whether this drug is excreted in human milk. Since many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Hydrocortisone Acetate Suppositories, a decision should be made whether to discontinue nursing or to discontinue taking the drug, taking into account the importance of the drug to the mother.

Until adequate studies in pregnant or lactating women have been conducted, this drug should be used during pregnancy or by nursing mothers only when clearly needed and when the potential benefits outweigh the potential risks to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported with Hydrocortisone Acetate Suppositories:

  • Burning
  • Itching
  • Irritation
  • Dryness
  • Folliculitis
  • Hypopigmentation
  • Allergic Contact Dermatitis
  • Secondary Infection

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

Drug abuse and dependence have not been reported in patients treated with Hydrocortisone Acetate Suppositories.

OVERDOSAGE

OVERDOSAGE SECTION

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Usual dosage:

SPL UNCLASSIFIED SECTION

One suppository in the rectum twice daily morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

HOW SUPPLIED

HOW SUPPLIED SECTION

Hydrocortisone Acetate Suppositories are easy to open, color coded and available in cartons of:

12'sNDC 0574-7093-12

STORAGE AND HANDLING SECTION

Store at controlled room temperature 15°- 30° C (59° - 86° F).

SPL UNCLASSIFIED SECTION

Paddock Laboratories, Inc.
Minneapolis, MN 55427

(04-05)

PRINCIPAL DISPLAY PANEL - 30 mg Packet Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Hydrocortisone Acetate 30 mg
Suppository
(01) 10305747093122
Paddock Laboratories, Inc.
Minneapolis, MN 55427

PRINCIPAL DISPLAY PANEL - 30 mg Packet Label
PRINCIPAL DISPLAY PANEL - 30 mg Packet Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0574-7093-12EA - Each0574-7093233c1cdd-ed8b-4513-a4fa-c1a544a2664912013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
HYDROCORTISONE ACETATEACTIVE INGREDIENT3X7931PO741
HYDROCORTISONEACTIVE MOIETYWI4X0X7BPJ1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0574-70930574-7093-12

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
HYDROCORTISONE ACETATE3X7931PO74ACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Hydrocortisone AcetateHYDROCORTISONE ACETATEPadagis US LLC2fdb9940-6da8-49b0-a236-9817943f7a4b2022-05-31Adverse reactionsExact identifier
ndc (package): 0574-7093-12
ndc (product): 0574-7093
ndc11 (package): 00574709312
c47f2d23-f2d7-43ad-899c-356d3b3dabfd70714f21-5a4a-4ed3-8cda-5c271bd2c5942012-08-17Adverse reactionsExact identifier
spl id: c47f2d23-f2d7-43ad-899c-356d3b3dabfd
spl set id: 70714f21-5a4a-4ed3-8cda-5c271bd2c594

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.